Biomedical subjects

Simona Balestrini

Publications and source records attributed to Simona Balestrini.

3 recordsLinked to original sources

PubMed2025

The burden of TTN variants in the genomic era: Analysis of 18,462 individuals from the Solve-RD consortium and general recommendations.

PURPOSE: Titin, the largest protein in the human body, has been associated with several disease phenotypes caused by variants in the TTN gene. With around 20% of the population carrying a rare TTN variant and over 60 million genomes expected to have been sequenced worldwide by 2025, interpreting these findings presents major challenges. This study analyzed TTN variants in the Solve-RD cohort, the European network for unsolved rare disease cases. METHODS: We collected data from 11,072 individuals with suspected rare diseases and 7390 healthy relatives from the Solve-RD consortium, checking and manually reviewing TTN variants. We then used a filtering approach focused on clinical relevance, and we provided updated recommendations based on recent literature. RESULTS: Among the cohort, 240 individuals (1.3%) carried at least one heterozygous TTN truncating variant (TTNtv), with a 3.8% prevalence in the neuromuscular subgroup, primarily composed of unsolved cases. Four individuals received a titinopathy diagnosis. Additionally, 99 participants (0.5%) had a TTNtv in a high cardiac percent spliced in exon (>80%), and 4 had an overt cardiomyopathy. CONCLUSION: This study highlights the need for standardized approach to TTN variants, and investigation of missing heritability in individuals with skeletal myopathy with het TTNtv. Establishing consensus on percent spliced in-based thresholds will be essential for assessing cardiac risk and guiding the management of asymptomatic individuals.

Humans↗

PubMed2025

COL4A1 and COL4A2-related disorders: Clinical features, diagnostic guidelines, and management.

PURPOSE: Collagen type 4 alpha 1 (COL4A1) and alpha 2 (COL4A2) chains, encoded by COL4A1 and COL4A2, are essential for basement membrane integrity, contributing to structural stability and cell regulation. Pathogenic variants in these genes cause a spectrum of autosomal dominant and, more rarely, autosomal recessive disorders, which are collectively known as COL4A1/A2-related disorders. These multisystem disorders can include neurologic, ophthalmologic, renal, and other organ system pathology and vary widely in symptoms, complicating diagnosis and management. METHODS: Using a modified eDelphi method, we obtained consensus from international experts across medical subspecialties on the evaluation and management of COL4A1/A2-related disorders, with consensus set at ≥70% agreement. RESULTS: Consensus was achieved on recommendations for evaluating and managing these conditions. CONCLUSION: Genetic testing and counseling are advised for individuals showing symptoms of COL4A1/A2-related disorders and for at-risk relatives. Given the complexity and rarity of these disorders, management requires a multidisciplinary approach informed by current understanding of disease mechanisms. Recommended care includes neurological and ophthalmological imaging and monitoring of cardiovascular and renal function. Ongoing research is critical to uncover genotype-phenotype links and potential modifiers, with clinical research participation encouraged to advance knowledge and treatments.

Humans↗

PubMed2025

TMS-EEG in postictal psychosis of epilepsy.

BACKGROUND: Postictal psychosis (PIP) is a poorly understood complication affecting 2 % of individuals with epilepsy. Genomic and neuroimaging studies suggest parallels with schizophrenia. OBJECTIVES: To determine whether Transcranial Magnetic Stimulation coupled with Electroencephalography (TMS-EEG), can reveal schizophrenia-like changes in PIP, especially in Natural Frequency (NF), gamma band Event-Related Spectral Perturbation (ERSP), the N100 peak, and global mean field power (GMFP). METHODS: We applied TMS-EEG targeting the non-dominant hemisphere premotor area in people with focal epilepsy (PWE) with a history of PIP (n = 7) and PWE without any history of psychosis (n = 14). Two-tailed t-tests were applied to TMS-EEG metrics previously studied in schizophrenia to look for differences between the groups, with subgroup analyses excluding participants using benzodiazepines. RESULTS: Demographic and clinical characteristics were similar across the two groups. No significant differences were seen in NF (p = 0.98). We observed a delayed N100 peak latency in the PIP group when excluding those with regular benzodiazepine use (p = 0.05) and increased global mean field power during the 400-600 ms phase of the TEP (p = 0.02). Mean ERSP within the gamma band was lower in the PIP group, though this did not reach statistical significance (p = 0.08). CONCLUSION: This is the first study to apply TMS-EEG in individuals with PIP, demonstrating feasibility and providing methodological insights for future studies. Preliminary findings, including increased GMFP and delayed N100 latency in PIP, suggest possible disruptions in cortical excitability similar to schizophrenia, warranting further investigation.

Humans↗